

August 3, 2020

Dear Fellow Stockholder,

I write to you today with gratitude for your support of Bionano Genomics and our critical mission to improve lives by making the Saphyr system and Bionano data cornerstones of genome analysis. The purpose of this letter is to outline the reasons for you to support and vote “FOR” Proposal 1 contained in the Definitive Proxy Statement for our Special Meeting of Stockholders to be held on August 31, 2020 at 10:00 a.m. Pacific Time.

As you may recall, we had proposed certain amendments to Bionano’s Amended and Restated Certificate of Incorporation in connection with the Annual Meeting of Stockholders held on June 30, 2020. This proposal was designed to accomplish two tasks: (1) authorize the board of directors to effect a reverse stock split with ratios in the range of 1-for-10 to 1-for-20; and (2) double the number of Bionano’s authorized shares of common stock by reducing authorized shares at a ratio of 1-for-2 in proportion to the selected reverse stock split ratio. The purpose of the reverse stock split component of the proposal was to enable Bionano to regain compliance with certain listing requirements of the Nasdaq Capital Market.

After speaking with many stockholders, I developed an understanding that the reverse stock split was something they did not support. This proposal did not pass, and a reverse stock split is not something we are seeking to implement at the current time. I am thankful to all of you who took the time to express your views. It was incredibly helpful to hear what you had to say.

By not approving the reverse stock split component of this proposal, however, the related increase in authorized shares did not pass because the two concepts were joined together in the same proposal. While the reverse stock split is not something we needed urgently, the increase in authorized shares is critical.

At the current level of authorized shares, we are unable to confidently take the necessary steps to move the company forward in key strategic and financial areas. We believe the increase will enable us to, among other things, execute future potential equity financings, recruit and retain exceptional talent, and pursue potential strategic transactions.

Therefore, I would like to ask that you please support Proposal 1 as described in the Proxy Statement, which is for an increase in authorized shares without any reverse split component. We believe that doing so will give Bionano a much better chance of succeeding in its core mission.

Thank you for your attention.

Sincerely,

/s/ Erik Holmlin
Erik Holmlin
President and CEO
Bionano Genomics, Inc.

